Erica Simone Dayan - Concepedia

Author

Erica Simone Dayan

Memorial Sloan Kettering Cancer Center ORCID

Also Known As

E. Cohn, E.D. Cohn, Erica Cohn, Erica D. Cohn, Erica Dayan, Erica Dayan Cohn, Erica S. Dayan, Erica S. Dayan Cohn, Erica Simone Dayan, Holland, Jaymes

Publications

217

Citations

H-Index

Concepts

All Affiliations

Memorial Sloan Kettering Cancer Center Cornell University Sidney Kimmel Comprehensive Cancer Center The Barbara Ann Karmanos Cancer Institute UNC Lineberger Comprehensive Cancer Center

About

Erica Simone Dayan is an author at Memorial Sloan Kettering Cancer Center specializing in urology, pharmacotherapy, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	92
2	Health Sciences	1	1	12
3	Endocrinology	1	1	12
4	Obstetrics	1	1	10
5	Pharmacology	1	1	70

Erica Simone Dayan

Publications

177

Citations

H-Index

Page 1

	Year	Citations
A Pilot Study of a Multimodal Treatment Paradigm to Accelerate Drug Evaluations in Early-stage Metastatic Prostate Cancer Matthew J. O’Shaughnessy, Sean M. McBride, Hebert Alberto Vargas, Urology UrologyAccelerate Drug EvaluationsPreclinical Drug EvaluationMedicinePharmacology	2016	70
Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint Ethan Basch, Mark C. Scholz, Johann S. de Bono, European Urology	2018	57
Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy Karen A. Autio, Emmanuel S. Antonarakis, Tina Mayer, European Urology Open Science	2021	17
A phase II study combining ipilimumab and degarelix with or without radical prostatectomy (RP) in men with newly diagnosed metastatic noncastration prostate cancer (mNCPC) or biochemically recurrent (BR) NCPC. Karen A. Autio, James A. Eastham, Daniel C. Danila, Journal of Clinical Oncology Surgical OncologyImmunodeficienciesPhase Ii StudyPharmacotherapyImmunotherapy	2017	12
Spine Pain and Metastatic Prostate Cancer: Defining the Contribution of Nonmalignant Etiologies Lisa Marie Ruppert, Erica Simone Dayan, Niamh M. Keegan, JCO Oncology Practice	2022	11
Efficacy analysis of a phase III study of androgen deprivation therapy (ADT) +/- docetaxel (D) for men with biochemical relapse (BCR) after prostatectomy. Michael J. Morris, Patrick Hilden, Martin Gleave, Journal of Clinical Oncology Surgical OncologyMetastatic Cspc LiveGynecologySurgeryPharmacotherapy	2015	10

Page 1